TRANSTHERA-B

2617
7.2604.16% ( -0.315 )
Delay Closed: Nov 16, 16:08:11

Overview

TRANSTHERA-B (2617)

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, infla...

Open
7.800
High
7.800
Low
7.220
Prev. Close
7.575
Volume
2.10M
Turnover
15.54M
Avg Price
7.397
Bid/Ask Ratio
0.00%
Amplitude
7.66%
52wk High
221.400
Volume Ratio
0.21
Turnover Ratio
0.67%
52wk Low
7.220
HK Mkt Cap
2.27B
Market CapHKD
2.96B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.758
EPSDynamic
-0.539
EPSStatic
--
BVPS
2.48
P/B
2.93
HK Shares
312.43M
Dividend YieldTTM
--
DividendTTM
--
Shares
407.66M
Min lot size
500
Currency
HKD

TRANSTHERA-B Analyst Rating

View more

Forecast & Rating

Jul 9, 2026
Price forecast
HK$18.69157.42%
Forecast & Rating-

Daily Events

  1. Nov, 13

    TransThera (2617.HK) spiked then faded to close down 4.95% at HK$7.58, having touched HK$8.055 in the morning session and HK$7.570 in the afternoon on 2.62 million shares worth about HK$20.28 million and a thin 0.84% turnover rate, as approval to convert 44,971,128 domestic unlisted shares into H shares, with the CSRC filing completed, stoked share-count expansion concerns in an already shallow book. Q2 2026 revenue was HK$20.48 million with a net loss of HK$55.13 million, narrowing 18.1% year on year, and a loss per share of HK$0.1373, while lead asset Tinengotinib remains at the registration-stage clinical phase and the national rollout of cholangiocarcinoma drug Yochanra has yet to convert into revenue. The stock is down 93.3% year to date, 96.92% below its 52-week high of HK$246, just 0.66% above its 52-week low of HK$7.53, and trades under both its MA20 of HK$8.40 and MA60 of HK$9.50. Though repeated share buyback disclosures on the HKEX may offer some cushion.

  2. Nov, 5

    Led by a run of share buybacks and a 98-point gain in the Hong Kong market, Transthera-B opened higher and finished at HK$8.345, up 5.2% from the previous close of HK$7.930, after touching an intraday high of HK$8.400 from a HK$7.995 low and easing only modestly in the afternoon session. The company repurchased 56,500 shares for HK$454,600 on November 2, after 32,500 shares for HK$280,300 on October 27 and 52,500 shares for HK$467,000 on October 26, while the HKEX approved the conversion of 44,971,128 non-listed shares into H shares, about 11% of equity, keeping potential supply in focus. Q2 revenue was HK$20.48 million and net loss HK$55.13 million, narrowing 18.1% year on year, with EPS of -HK$0.1373, PE at -11x and PB at 3.37x, on a market capitalization of about HK$3.40 billion and a 1.92% turnover rate; total volume was 5.99 million shares with daily turnover of HK$49.4 million. The stock remains below its 20-day moving average of HK$8.923 and 60-day average of HK$9.735, down 92.63% year to date and 96.61% below its 52-week high of HK$246, though buybacks offer some support to the stock.

  3. Nov, 3

    TransThera-B (2617.HK) reversed intraday gains to close down 1.1% at HK$7.81, as the HKEX approval to list 44,971,128 unlisted domestic shares converted into H shares, about 11% of equity, kept dilution concerns alive after the stock fell 6% in the prior session on the same news. The session traced a high of HK$8.455 in the morning and a low of HK$7.755 in the afternoon, with turnover of 5.61 million shares worth HK$45.22 million. The close sits only 3.72% above the 52-week low of HK$7.53, down 93.1% year to date and 96.83% below the 52-week high of HK$246, while remaining under the 20-day MA of HK$9.12 and 60-day MA of HK$9.824. For Q2, revenue was HK$20.48 million and net loss HK$55.13 million, with the loss narrowing 18.1% year on year and EPS improving 22.04% to -HK$0.1373; negative PE, 3.15x PB and ROE of -21.75% indicate profitability has not turned positive. The company bought back 56,500 shares for HK$454,600 on November 2, though the amount remains small relative to the 11% conversion.

  4. Oct, 27

    TransThera Sciences fell 4.34% to HK$8.480 from HK$8.865, opening up at HK$8.980 before sliding through the morning to an afternoon low of HK$8.430, after the CSRC accepted its filing to convert 44,971,128 domestic shares into H shares, feeding expectations of a larger free float. Partial offset came from buybacks on October 22 to 26 totaling 110,500 shares for about HK$973,000, plus Jientai®, whose first clinical prescriptions were issued across multiple provinces with nationwide DTP pharmacy stocking, and the rollout of Yochanra, China's first domestically developed cholangiocarcinoma drug. Q2 2026 revenue was HK$20.48 million with a net loss of HK$55.13 million, narrowing 18.1% year on year. The stock is down 92.51% year to date, trades below its MA20 of HK$9.648 and MA60 of HK$10.069, and sits just 1.56% above its 52-week low of HK$8.35 against a HK$246 high. Though losses persist, a 3.42x PB leaves little earnings anchor.

  5. Oct, 23

    TransThera-B (2617.HK) rebounded off its session low on Thursday: it dipped to HK$8.35 at 09:38 BJ, recovered to HK$8.945 by 11:22, and closed at HK$8.805, up 3.10% from the HK$8.54 prior close, on 3.363m shares worth roughly HK$29.4m. The move followed first clinical prescriptions for Jientai (Yochanra), China's first homegrown cholangiocarcinoma drug, in multiple provinces alongside nationwide DTP pharmacy stocking, plus a HK$47,200 repurchase of 5,500 shares on Oct 22. Fundamentals remain loss-making: Q2 revenue of about HK$20.5m and a net loss of HK$55.1m, 18.1% narrower YoY, with EPS at -HK$0.1373. The shares set a 52-week low of HK$8.35 yesterday, are down 92.22% YTD, sit 96.42% below the HK$246 peak, and remain under the MA20 of HK$9.799 and MA60 of HK$10.109. Though the buyback is small and rollout cadence is unproven.

News